Inhibitory activities of medicinal mushrooms on α-amylase and α-glucosidase-enzymes related to type 2 diabetes

• Published in: South African journal of botany 2021-03, Vol.137, p.19-23
• Main Authors: Deveci, Ebru, Çayan, Fatih, Tel-Çayan, Gülsen, Duru, Mehmet Emin
• Format: Article
• Language: English
• Subjects: Extract; Mushrooms; Type 2 diabetes; α-amylase; α-glucosidase
• ISSN: 0254-6299; 1727-9321
• DOI: 10.1016/j.sajb.2020.09.039

•Antidiabetic activities of the extracts of twenty-four mushrooms were tested.•This is the first study on antidiabetic activities of studied mushroom hexane extracts.•Mushroom extracts possessed significiantly high antidiabetic activity.•Studied mushroom species can be used as promising natural antidiabetic agents. Mushrooms have been used as a primary source of medicines since ancient times due to the presence of bioactive compounds. Enzyme inhibition is an important field of pharmaceutical research that provides insight into the discovery of a large variety of drugs that are useful in treating many diseases. The inhibitory activities of the hexane and methanol extracts of twenty-four medicinal mushrooms on α-amylase and α-glucosidase enzymes related to type 2 diabetes were evaluated in this study. Among all studied mushroom extracts, C. rutilus hexane extract (IC50: 0.05±0.01 mg/mL) demonstrated the highest inhibitory activity on α-amylase while P. ostreatus hexane (IC50: 0.10±0.01 mg/mL) showed the highest inhibitory activity on α-glucosidase. The hexane extracts of C. rutilus (98.81±0.01 %), G. adspersum (96.96±0.47 %), G. sepiarium (96.89±1.01 %), and S. granulatus (97.74±0.27 %) displayed higher inhibitory activity on α-amylase enzyme than acarbose at 1.00 mg/mL concentration. Also, the hexane extracts of P. ostreatus (IC50: 0.10±0.01 mg/mL), M. procera (IC50: 0.11±0.01 mg/mL), P. schweinitzii (IC50: 0.14±0.01 mg/mL), L. gentianeus (IC50: 0.22±0.02 mg/mL), P. pini (IC50: 0.22±0.03 mg/mL) and the methanol extracts of T. pubescens (IC50: 0.12±0.02 mg/mL) and G. adspersum (IC50: 0.20±0.04 mg/mL) showed higher inhibitory activity on α-glucosidase enzyme than acarbose (IC50: 0.37±0.01 mg/mL). This study with the reported results supported the use of mushrooms in the pharmaceutical industries as natural antidiabetic agents through key enzyme inhibition.